JY
NPCE icon

Jeff Yass’s Neuropace NPCE Stock Holding History

Jeff Yass’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Sell
10,154
-15,026
-60% -$242K ﹤0.01% 12147
2026
Q1 		$331K Buy
25,180
+15,059
+149% +$226K ﹤0.01% 10656
2025
Q4 		$156K Buy
+10,121
New +$135K ﹤0.01% 11131
2025
Q3 		– Sell
-29,197
Closed -$275K – 13418
2025
Q2 		$325K Buy
29,197
+9,288
+47% +$116K ﹤0.01% 10157
2025
Q1 		$245K Buy
19,909
+7,295
+58% +$91.3K ﹤0.01% 10515
2024
Q4 		$141K Buy
+12,614
New +$110K ﹤0.01% 11065
2024
Q2 		– Sell
-203,776
Closed -$2.06M – 12858
2024
Q1 		$2.69M Buy
203,776
+161,491
+382% +$2.3M ﹤0.01% 4719
2023
Q4 		$436K Buy
+42,285
New +$337K ﹤0.01% 9001
2023
Q2 		– Sell
-14,052
Closed -$65.2K – 12793
2023
Q1 		$65.2K Buy
+14,052
New +$53.8K ﹤0.01% 11568

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Jeff Yass's NPCE Position: Q2 2026 in Review

Jeff Yass reduced its Neuropace (NPCE) stake by 60% in Q2 2026, selling an estimated $242K and leaving 10,154 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #12147.

Jeff Yass first reported a position in NPCE in Q1 2023 and has held it in 9 quarters since. The position peaked at $2.69M in Q1 2024. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Jeff Yass held 10,154 shares of Neuropace worth $161K as of Q2 2026.
  • Jeff Yass sold 15,026 Neuropace shares in Q2 2026, an estimated $242K.
  • Neuropace made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12147 holding.
  • Jeff Yass first reported a position in Neuropace in Q1 2023 and has held it in 9 quarters since.
  • Jeff Yass's Neuropace position peaked at $2.69M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.